Evidence map›Paper›PMID 35120165›Full record

ArticlePloS one2022

Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease.

Maria Sabater Molina, Elisa Nicolás Rocamora, Asunción Iborra Bendicho, Elisa García Vázquez, Esther Zorio, Fernando Domínguez Rodriguez, Cristina Gil Ortuño, Ana Isabel Rodríguez, Antonio J Sánchez-López, Rubén Jara Rubio and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 4 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Role ofAfrican journal of laboratory medicine · 2024
    Article
  17. Frontiers in medicine · 2024
    Article
  18. Predictive Factors andInternational journal of molecular sciences · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Maria Sabater MolinaCardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.ORCID 0000-0003-1352-1748
Elisa Nicolás RocamoraCardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Asunción Iborra BendichoMicrobiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Elisa García VázquezDepartment of Infectious Disease, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Esther ZorioCentro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain.
Fernando Domínguez RodriguezCentro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain.
Cristina Gil OrtuñoCardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Ana Isabel RodríguezCardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Antonio J Sánchez-LópezBiobanco Hospital Universitario Puerta de Hierro/Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Rubén Jara RubioIntensiveCareUnit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Antonio Moreno-DocónMicrobiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Pedro J MarcosCentro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain.
Pablo García PavíaCentro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain.
Roberto Barriales VillaCentro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain.ORCID 0000-0002-6721-3487
Juan R Gimeno BlanesCardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Hospital Universitario Virgen de la Arrixaca · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario Puerta de Hierro Majadahonda · ESInstituto Murciano de Investigación Biosanitaria · ESUniversidad Francisco de Vitoria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection by the SARS-Cov-2 virus produces in humans a disease of highly variable and unpredictable severity. The presence of frequent genetic single nucleotide polymorphisms (SNPs) in the population might lead to a greater susceptibility to infection or an exaggerated inflammatory response. SARS-CoV-2 requires the presence of the ACE2 protein to enter in the cell and ACE2 is a regulator of the renin-angiotensin system. Accordingly, we studied the associations between 8 SNPs from AGTR1, ACE2 and ACE genes and the severity of the disease produced by the SARS-Cov-2 virus.

methods318 (aged 59.6±17.3 years, males 62.6%) COVID-19 patients were grouped based on the severity of symptoms: Outpatients (n = 104, 32.7%), hospitalized on the wards (n = 73, 23.0%), Intensive Care Unit (ICU) (n = 84, 26.4%) and deceased (n = 57, 17.9%). Comorbidity data (diabetes, hypertension, obesity, lung disease and cancer) were collected for adjustment. Genotype distribution of 8 selected SNPs among the severity groups was analyzed.

resultsFour SNPs in ACE2 were associated with the severity of disease. While rs2074192 andrs1978124showed a protector effectassuming an overdominant model of inheritance (G/A vs. GG-AA, OR = 0.32, 95%CI = 0.12-0.82; p = 0.016 and A/G vs. AA-GG, OR = 0.37, 95%CI: 0.14-0.96; p = 0.038, respectively); the SNPs rs2106809 and rs2285666were associated with an increased risk of being hospitalized and a severity course of the disease with recessive models of inheritance (C/C vs. T/C-T/T, OR = 11.41, 95% CI: 1.12-115.91; p = 0.012) and (A/A vs. GG-G/A, OR = 12.61, 95% CI: 1.26-125.87; p = 0.0081). As expected, an older age (OR = 1.47), male gender (OR = 1.98) and comorbidities (OR = 2.52) increased the risk of being admitted to ICU or death vs more benign outpatient course. Multivariable analysis demonstrated the role of the certain genotypes (ACE2) with the severity of COVID-19 (OR: 0.31, OR 0.37 for rs2074192 and rs1978124, and OR = 2.67, OR = 2.70 for rs2106809 and rs2285666, respectively). Hardy-Weinberg equilibrium in hospitalized group for I/D SNP in ACE was not showed (p<0.05), which might be due to the association with the disease. No association between COVID-19 disease and the different AGTR1 SNPs was evidenced on multivariable, nevertheless the A/A genotype for rs5183 showed an higher hospitalization risk in patients with comorbidities.

conclusionsDifferent genetic variants in ACE2 were associated with a severe clinical course and death groups of patients with COVID-19. ACE2 common SNPs in the population might modulate severity of COVID-19 infection independently of other known markers like gender, age and comorbidities.

Indexed as

Polymorphism, Single NucleotideSeverity of Illness IndexAgedAngiotensin-Converting Enzyme 2COVID-19FemaleGenotypeHumansMaleMiddle AgedPeptidyl-Dipeptidase AReceptor, Angiotensin, Type 1SARS-CoV-2ACE2 protein, humanACE protein, humanAGTR1 protein, humanAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase AReceptor, Angiotensin, Type 1

Identifiers

PMID35120165
PMCPMC8815985
OpenAlexW4210404056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.